Strategies for successful rapid trials of influenza vaccine

Clinical Trials

Volumn 8, Issue 6, 2011, Pages 699-704

  Scheifele, David W ^a,b   Marty, Kim ^a,b   Lajeunesse, Carol ^a,b   Fan, Shu Yu ^a,b   Bjornson, Gordean ^a,b   Langley, Joanne M ^b,c   Halperin, Scott A ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; CANADA; EXPOSURE; HEALTH CARE PLANNING; HUMAN; INFLUENZA VIRUS A H1N1; INTERNET; PANDEMIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION;

ADULT; CANADA; CLINICAL TRIALS AS TOPIC; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INFORMATION MANAGEMENT; MIDDLE AGED; PATIENT SELECTION; PERSONNEL SELECTION; RESEARCH DESIGN; TIME FACTORS; YOUNG ADULT;

EID: 83455169029     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511419868     Document Type: Article

References (19)

1. Pollard AJ, Kerner A, John T, et al. Expediting clinical trials in a pandemic. BMJ. 2009 ; 339: 1099-100
2. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomized controlled phase 2 trials. Lancet. 2010 ; 375: 41-48
3. Wu J, Li W, Wang HQ, et al. A rapid immune response to 2009 influenza A (H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis. 2010 ; 202: 675-80
4. Greenberg ME, Lai MH, Hartel GF, et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine-preliminary report. N Engl J Med. 2009 ; 361: 2405-13
5. Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine. 2011 ; 29: 523-27
6. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet. 2010 ; 375: 56-66
7. Scheifele DW, Ward BJ, Dionne M, et al. Evaluation of adjuvanted pandemic H1N12009 influenza vaccine after one and two doses in young children. Pediatr Infect Dis J. 2011 ; 30: 402-07
8. French MB, Loeb MB, Richardson C, Singh B. Research preparedness paves the way to respond to pandemic H1N1 2009 influenza virus. Can J Infect Dis Med Microbiol. 2009 ; 20: e63-66
9. Scheifele DW, Dionne M, Ward B, et al. Safety and immunogenicity of re-vaccination with H1N1-containing 2010-2011 seasonal influenza vaccine after priming with 2009 adjuvanted pandemic vaccine. Proceedings of the 14th Annual Conference on Vaccine Research ; Baltimore, MD ;.
10. Scheifele DW, Duval B, Russell ML, et al. Ocular and respiratory syndromes attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis. 2003 ; 36: 850-57 (Pubitemid 36403517)
11. Scheifele D, Duval B, De Serres G, Skowronski DM. Unique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications. Control Clin Trials. 2003 ; 24: 99-104 (Pubitemid 36135952)
12. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children. JAMA. 2010 ; 303: 37-46
13. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12years: open label, randomized, parallel group, multicentre trial. Br Med J. 2010 ; 340: c2649
14. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009 ; 361: 2414-23
15. Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-containing 2009 influenza A (H1N1) vaccines: a randomized, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis. 2011 ; 11: 91-101
16. Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine. 2010 ; 28: 5837-44
17. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 Influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009 ; 361: 2424-35
18. Langley JM, Scheifele D, Quach C, et al. Rapid pre-season trial of the safety of 2010-2011 H1N1-containing trivalent inactivated influenza vaccine (TIV) in young children 12 to 59 months of age who received AS03-adjuvanted H1N12009 pandemic vaccine; a PHAC/CIHR Influenza Research Network study. Proceedings of the 14th Annual Conference on Vaccine Research ; Baltimore, MD ;.
19. Gold MS, Effor P, Kelly H, et al. Febrile convulsions after 2010 seasonal trivalent influenza vaccine: implications for vaccine safety surveillance in Australia. Med J Aust. 2010 ; 193: 492-93